Specifically, therapeutic benefits have been proposed for blocking the C5a-C5aR1-axis in several inflammatory disorders (Schanzenbacher et al. 2023), seeming to be especially effective against another systemic small-vessel vasculitis called anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), where neutrophils become activated by ANCAs. The gene discussed is C5AR1; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.